Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease.
GFAP
amyloid‐beta
atypical Alzheimer's disease
tau
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
revised:
02
01
2024
received:
25
09
2023
accepted:
03
01
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
Glial fibrillary acidic protein (GFAP) in plasma is a proxy for astrocytic activity and is elevated in amyloid-β (Aβ)-positive individuals, making GFAP a potential blood-based biomarker for Alzheimer's disease (AD). We assessed plasma GFAP in 72 Aβ-positive participants diagnosed with the visual or language variant of AD who underwent Aβ- and tau-PET. Fifty-nine participants had follow-up imaging. Linear regression was applied on GFAP and imaging quantities. GFAP did not correlate with Aβ- or tau-PET cross-sectionally. There was a limited positive correlation between GFAP and rates of tau accumulation, particularly in the language variant of AD, although associations were weaker after removing one outlier patient with the highest GFAP level. Among Aβ-positive AD participants with atypical presentations, plasma GFAP did not correlate with levels of AD pathology on PET, suggesting that the associations between GFAP and AD pathology might plateau during the advanced phase of the disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : R01-AG50603
Pays : United States
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Liddelow SA, Guttenplan KA, Larke LEC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481‐487. doi:10.1038/nature21029
Shir D, Day GS. Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody‐mediated encephalitis and coronavirus disease 2019. Curr Opin Neurol. 2022;35(2):212‐219. doi:10.1097/Wco.0000000000001033
Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol. 2013;239:133‐138. doi:10.1016/j.expneurol.2012.10.007
Benedet AL, Mila‐Aloma M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471‐1483. doi:10.1001/jamaneurol.2021.3671
Ferreira PCL, Therriault J, Tissot C, et al. Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 2023;19(10):4463‐4474. doi:10.1002/alz.13393
Shir D, Graff‐Radford J, Hofrenning EI, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimer Dement. 2022;14(1):e12291. doi:10.1002/dad2.12291
Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer's disease: a systematic review and meta‐analysis. Cells‐Basel. 2023;12(9):1309. doi:10.3390/cells12091309
Stevenson‐Hoare J, Heslegrave A, Leonenko G, et al. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain. 2023;146(2):690‐699. doi:10.1093/brain/awac128
Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid‐beta but not tau pathology in Alzheimer's disease. Brain. 2021;144:3505‐3516. doi:10.1093/brain/awab223
Asken BM, Elahi FM, La Joie R, et al. Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage (vol 78, pg 265, 2020). J Alzheimers Dis. 2021;80(1):471‐474. doi:10.3233/Jad‐219001
Chatterjee P, Vermunt L, Gordon BA, et al. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: associations with Abeta‐PET, neurodegeneration, and cognition. Alzheimers Dement. 2023;19(7):2790‐2804. doi:10.1002/alz.12879
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical‐scale for the staging of dementia. Brit J Psychiat. 1982;140:566‐572. doi:10.1192/bjp.140.6.566
Rodriguez‐Vieitez E, Saint‐Aubert L, Carter SF, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain. 2016;139:922‐936. doi:10.1093/brain/awv404
Bellaver B, Povala G, Ferreira PCL, et al. Astrocyte reactivity influences amyloid‐beta effects on tau pathology in preclinical Alzheimer's disease. Nat Med. 2023;29(7):1775‐1781. doi:10.1038/s41591‐023‐02380‐x
Ferrari‐Souza JP, Ferreira PCL, Bellaver B, et al. Astrocyte biomarker signatures of amyloid‐beta and tau pathologies in Alzheimer's disease. Mol Psychiatr. 2022;27(11):4781‐4789. doi:10.1038/s41380‐022‐01716‐2
Salvado G, Ossenkoppele R, Ashton NJ, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15(5):e17123. doi:10.15252/emmm.202217123
Graff‐Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222‐234. doi:10.1016/S1474‐4422(20)30440‐3
Sintini I, Graff‐Radford J, Senjem ML, et al. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. Brain. 2020;143:2281‐2294. doi:10.1093/brain/awaa155
Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170‐178. doi:10.1016/S1474‐4422(11)70289‐7
Gorno‐Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006‐1014. doi:10.1212/WNL.0b013e31821103e6
Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer Dement. 2017;13(3):205‐216. doi:10.1016/j.jalz.2016.08.005
Sintini I, Graff‐Radford J, Schwarz CG, et al. Longitudinal rates of atrophy and tau accumulation differ between the visual and language variants of atypical Alzheimer's disease. Alzheimers Dement. 2023;19(10):4396‐4406. doi:10.1002/alz.13396
Graff‐Radford J, Arenaza‐Urquijo EM, Knopman DS, et al. White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142:2483‐2491. doi:10.1093/brain/awz162
Schwarz CG, Therneau TM, Weigand SD, et al. Selecting software pipelines for change in flortaucipir SUVR: balancing repeatability and group separation. Neuroimage. 2021;238:118259. doi:10.1016/j.neuroimage.2021.118259
Marks JD, Syrjanen JA, Graff‐Radford J, et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther. 2021;13(1):199. doi:10.1186/s13195‐021‐00944‐y
Syrjanen JA, Campbell MR, Algeciras‐Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128‐1140. doi:10.1002/alz.12466
Elahi FM, Casaletto KB, La Joiel R, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early‐ and late‐onset Alzheimer's. Alzheimers Dement. 2020;16(4):681‐695. doi:10.1016/j.jalz.2019.09.004
Jack CR, Wiste HJ, Lesnick TG, et al. Brain β‐amyloid load approaches a plateau. Neurology. 2013;80(10):890‐896.